Alzamend Neuro Completes Clinical Portion of Phase 2a Clinical Trial for Alzheimer’s Disease
Biopharmaceutical company, Alzamend Neuro, Inc., (Nasdaq: ALZN) has completed the clinical portion of its Phase 2a clinical trial evaluating a potential treatment for dementia in Alzheimer’s disease (AD). The company anticipates reporting topline data in June 2023.
The company’s lead product candidate, AL001, is a novel lithium-delivery system under development as an oral treatment for patients with dementia related to AD.
Highlights
- The multiple ascending dose (“MAD”) study’s purpose was to evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose in patients diagnosed with mild to moderate AD and healthy subjects.
- The study’s pharmacokinetic and statistical data are undergoing evaluation of the safety and tolerability of AL001.
- AL001 has the potential to deliver benefits of lithium carbonate while reducing or avoiding lithium toxicities, potentially providing clinicians with a major improvement over current lithium-based treatments.
About Alzamend Neuro
Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease, major depressive disorder and post-traumatic stress disorder. The company’s pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.
